ReviewNanomaterials (Basel, Switzerland)2021
Critical Review of Lipid-Based Nanoparticles as Carriers of Neuroprotective Drugs and Extracts.
Review in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 75 citations in OpenAlex.
- Holdfast-Derived Lipid Extract from the Patagonian MacroalgaPharmaceuticals (Basel, Switzerland) · 2026Article
- Solid lipid nanoparticles as carriers forFrontiers in aging neuroscience · 2026Article
- Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead.AAPS PharmSciTech · 2025Review
- Valorization of Olive Leaf Extract via Tailored Liposomal Carriers: Comparative Analysis of Physicochemical Features, Antioxidant Capacity, and Stability.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Advances in Oral Drug Delivery Systems for Natural Polyunsaturated Fatty Acids: Enhancing Bioavailability and Therapeutic Potential.Pharmaceutics · 2025Review
- The silent saboteur: oxidative stress and the path to cognitive dysfunction.Neurodegenerative disease management · 2025Review
- A Review of Formulation Strategies for Cyclodextrin-Enhanced Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs).International journal of molecular sciences · 2025Review
- Enhancing Bioavailability and Stability of Plant Secondary Metabolites: Formulation and Characterization of Nanophytosomes Encapsulating Red Bryony and Horned Poppy Extracts.Journal of functional biomaterials · 2025Article
- The therapeutic potential of nanoencapsulated anti-inflammatory drugs delivered to the gut.Nanomedicine (London, England) · 2025Article
- Investigation of the anti-aging effects of active components of Artemia franciscana loaded in hyalurosome.Scientific reports · 2025Article
- Nano-structured strategies in combatting neurodegeneration.Frontiers in bioengineering and biotechnology · 2025Review
- Nasal Delivery of Phytochemicals Using Nanocarriers: Therapeutic Opportunities and Translational Challenges.International journal of nanomedicine · 2025Review
- Recent Advances in Bioactive Flavonoids-based Nanotherapeutics as Promising Neuroprotectants in Epilepsy.Current aging science · 2025Review
- Advancements in Phytosomal Therapies for Liver Cancer: A Comprehensive Review.Current cancer drug targets · 2025Review
- Nanomedicine in glaucoma treatment; Current challenges and future perspectives.Materials today. Bio · 2024Review
- ALKBH5-mediated m6A modification of IL-11 drives macrophage-to-myofibroblast transition and pathological cardiac fibrosis in mice.Nature communications · 2024Article
- Nanoparticles and Their Applications in Lipid Signaling.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Enhancement of the bioavailability of phenolic compounds from fruit and vegetable waste by liposomal nanocarriers.Food science and biotechnology · 2024Review
- Current status of nano-vaccinology in veterinary medicine science.Veterinary medicine and science · 2023Review
- A New Perspective for the Treatment of Alzheimer's Disease: Exosome-like Liposomes to Deliver Natural Compounds and RNA Therapies.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The biggest obstacle to the treatment of diseases that affect the central nervous system (CNS) is the passage of drugs across the blood-brain barrier (BBB), a physical barrier that regulates the entry of substances into the brain and ensures the homeostasis of the CNS. This review summarizes current research on lipid-based nanoparticles for the nanoencapsulation of neuroprotective compounds. A survey of studies on nanoemulsions (NEs), nanoliposomes/nanophytosomes and solid lipid nanoparticles (SLNs)/nanostructured lipid carriers (NLCs) was carried out and is discussed herein, with particular emphasis upon their unique characteristics, the most important parameters influencing the formulation of each one, and examples of neuroprotective compounds/extracts nanoencapsulated using these nanoparticles. Gastrointestinal absorption is also discussed, as it may pose some obstacles for the absorption of free and nanoencapsulated neuroprotective compounds into the bloodstream, consequently hampering drug concentration in the brain. The transport mechanisms through which compounds or nanoparticles may cross BBB into the brain parenchyma, and the potential to increase drug bioavailability, are also discussed. Additionally, factors contributing to BBB disruption and neurodegeneration are described. Finally, the advantages of, and obstacles to, conventional and unconventional routes of administration to deliver nanoencapsulated neuroprotective drugs to the brain are also discussed, taking into account the avoidance of first-pass metabolism, onset of action, ability to bypass the BBB and concentration of the drug in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.